- Home
- LCFY vs KLTO Comparison
LCFY vs KLTO Comparison
Compare LCFY & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- KLTO
- Stock Information
- Founded
- LCFY 2009
- KLTO 2019
- Country
- LCFY Australia
- KLTO United States
- Employees
- LCFY N/A
- KLTO N/A
- Industry
- LCFY
- KLTO
- Sector
- LCFY
- KLTO
- Exchange
- LCFY Nasdaq
- KLTO NYSE
- Market Cap
- LCFY 7.3M
- KLTO 7.6M
- IPO Year
- LCFY 2022
- KLTO N/A
- Fundamental
- Price
- LCFY $6.30
- KLTO $0.34
- Analyst Decision
- LCFY
- KLTO
- Analyst Count
- LCFY 0
- KLTO 0
- Target Price
- LCFY N/A
- KLTO N/A
- AVG Volume (30 Days)
- LCFY 19.2K
- KLTO 228.8K
- Earning Date
- LCFY 11-12-2024
- KLTO 11-26-2024
- Dividend Yield
- LCFY N/A
- KLTO N/A
- EPS Growth
- LCFY N/A
- KLTO N/A
- EPS
- LCFY N/A
- KLTO N/A
- Revenue
- LCFY $3,169,582.00
- KLTO N/A
- Revenue This Year
- LCFY N/A
- KLTO N/A
- Revenue Next Year
- LCFY N/A
- KLTO N/A
- P/E Ratio
- LCFY N/A
- KLTO N/A
- Revenue Growth
- LCFY N/A
- KLTO N/A
- 52 Week Low
- LCFY $2.20
- KLTO $0.26
- 52 Week High
- LCFY $11.23
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- LCFY 63.67
- KLTO N/A
- Support Level
- LCFY $5.54
- KLTO N/A
- Resistance Level
- LCFY $7.99
- KLTO N/A
- Average True Range (ATR)
- LCFY 0.39
- KLTO 0.00
- MACD
- LCFY 0.17
- KLTO 0.00
- Stochastic Oscillator
- LCFY 61.62
- KLTO 0.00
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.